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aneurysm screening program in Italy
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Objectives: Abdominal aortic aneurysm (AAA) is defined as a localized dilatation of an aortic vessel. Though predomi-
nantly asymptomatic, it is a chronic degenerative condition associated with life-threatening risk of rupture. The early
diagnosis of AAA, ie, before it ruptures, is therefore important; a simple, effective diagnostic method is ultrasound
examination. To assess the benefit of screening in Italy, we developed a cost-effective Markov model comparing screening
vs nonscreening scenarios.
Methods: A 13-health-states Markov model was developed to compare two cohorts of 65- to 75-year-old men: the first
group undergoing screening for AAA by means of ultrasound (US), the second following the current practice of
incidental detection. The following health states were distinguished: no AAA, unknown small AAA (3-3.9 cm),
followed-up small AAA (1 year), unknown medium-sized AAA (4-4.9 cm), followed-up medium-sized AAA (6 months),
unknown large AAA (>5 cm), elective repair, emergency repair, postelective-repair AAA, postemergency-repair AAA,
rejected large AAA, and death. Transitions between health states were simulated by using 6-month cycles. Transition
probabilities were derived from a literature review of relevant randomized controlled trial and from a screening program
that is currently ongoing at SanMartinoHospital in Genoa, Italy. The Italian National Health Service (NHS) perspective
was adopted and incremental cost per life-year saved was calculated with a lifetime horizon; costs and health benefits were
discounted at an annual rate of 3% from year 2 onward. Uncertainty surrounding the model inputs was tested by means
of univariate, multivariate, and probabilistic sensitivity analyses.
Results: Considering an attendance rate of 62%, the individual cost per invited subject was €60 (US $83.2); 0.011
additional quality adjusted life years (QALY) were gained per patient in the screened cohort, corresponding to an
incremental cost-effectiveness ratio (ICER) of €5673/QALY (US $7870/QALY). The results were sensitive to some
parameter variations but consistent with the base case scenario. They suggest that on the basis of a willingness-to-pay
threshold of €50,000/QALY, screening for AAA is cost-effective, with a probability approaching 100%.
Conclusions: As in economic evaluations developed in other countries, such as the UK, Canada, and The Netherlands,
setting up a screening program for AAA can be considered cost-effective from the Italian NHS perspective. ( J Vasc Surg
2011;54:938-46.)
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manent and irreversible condition caused by a failure of the
arterial wall that results in a dilatation with a diameter at
least 50% greater than normal,1 according to age, gender,
body size and other factors. AAA is a potentially lethal
disease. It commonly remains without symptoms or causes
no specific symptoms until its most serious complication,
rupture, which is one of the most serious emergencies in
vascular surgery. AAA rupture causes about 6000 deaths
per year in Italy. In 50% of cases, death occurs before the
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938atient reaches hospital, and among those who reach the
ospital alive, the mortality rate after emergency treatment
s 30% to 70%2-4; therefore, the overall mortality rate is
etween 65% and 85%.4
AAA rupture occurs mainly in men above 65 years old
ith an abdominal aortic diameter larger than 5 cm.5,6 The
ge-specific prevalence of the condition is six times greater
nmen than in women. It has been shown that AAA rupture
ccurs at a median age of 76 years in males and 81 years in
emales, and with a median diameter of 8 cm.7 By contrast,
he elective treatment of AAA that are detected early,
hether endovascular aneurysm repair (EVAR) or open
urgery (OS) is undertaken, is considered effective and safe,
ith a mortality rate 5%.8,9 These observations empha-
ize the importance of early diagnosis through ultrasound
US), a technique which is noninvasive, economical, and
ompletely sensitive. Several experiences have shown that
arly detection leads to a nearly 50% decrease in AAA
upture and to a reported drop in mortality with a reason-
ble cost-effectiveness.8,9
The aim of this study was to assess whether carrying out
national program of systematic AAA screening in Italy
ould be cost-effective according to the results of the
creening Abdominal Aortic Aneurysm Genova (S.A.Ge)
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Volume 54, Number 4 Giardina et al 939project, a pilot experience in Italy set up by the Vascular and
Endovascular Surgery Departments of San Martino Uni-
versity Hospital in Genova.
MATERIALS AND METHODS
Type of analysis. A cost-effectiveness analysis of two
alternative scenarios (screening for AAA vs current practice)
was conducted to assess the costs and benefits of screening
for AAA in Italy. Quality adjusted life years (QALY) and life
years saved (LYS) were used as indicators of effectiveness.
The cost-effectiveness results are reported in terms of the
comparison of the incremental cost per QALY/LYS gained
with or without implementing a screening program for
AAA and are expressed by the cost-effectiveness ratio
(ICER).
The Italian National Health Service (NHS) perspective
was adopted to evaluate resource consumption with a life-
long time-horizon, by applying a 3% discount to both costs
and health benefits from year 2 onward. Uncertainty re-
garding the assumptions made and the variability of the
parameters used in the model was tested by means of
probabilistic and multivariate deterministic sensitivity anal-
yses.
Model outline. A 13-health-states Markov model was
developed to compare two cohorts of 65- to 75-year-old
men: the first undergoing screening for AAA by means of
US, the second following the current practice of incidental
Fig 1. Current pathway. AAdetection. sThe Markov model comprised the following health
tates: no AAA, unknown small AAA (diameter 3-3.9 cm),
ollowed-up small AAA, unknown medium-sized AAA (di-
meter 4-4.9 cm), followed-up medium-sized AAA, un-
nown large AAA (diameter5 cm), elective repair, emer-
ency repair for ruptured AAA, emergency repair without
upture, postelective-repair AAA, postemergency-repair
AA, rejected large AAA, and death. Health states are
utually exclusive and collectively exhaustive, meaning
hat at any given time each subject is in one of the 13
ossible health states and cannot be in more than one state
t the same time.
The model is based on some key assumptions:
1) prevalence-based model;
2) “One-shot” screening: if during screening no AAA is
found, patients will not undergo a second US test;
3) US sensitivity is considered equal to 100%;
4) allows for incidental AAA detection in the nonscreened
population;
5) AAA 5 cm is assumed as the surgical threshold.
icrosoft Excel was used to develop theMarkovmodel and
o calculate the outcome and the consumption of resources
or each group of patients.
The model analyzes the pathway for subjects who, after
efusing a written invitation to undergo AAA screening,
ollow current practice (Fig 1), and the scenario in which
bdominal aortic aneurysm.ubjects agree to participate in the screening program (Fig
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October 2011940 Giardina et al2). Patients with a detected aneurysm that does not require
intervention are followed up by US every year (small AAA)
or every 6 months (medium AAA) according to the
follow-up protocol of the screening program (S.A.Ge)
developed at San Martino Hospital in Genova. The S.A.Ge
protocol included a follow-up visit every year for all patients
with a 3.0 to 3.9 cm aorta diameter and a follow-up every 6
months for aneurysm between 4.0 and 4.9 cm. All aneu-
rysms 5 cm were evaluated to receive elective repair.
When an aneurysm under surveillance reaches the interven-
tion threshold, the patient will move to the “elective repair”
state and then to the “postelective repair” or “death” state.
Patients with undiagnosed AAA will remain in the
“unknown AAA” state until an event occurs (AAA rupture,
emergency repair without rupture, death, incidental detec-
tion). If emergency repair is carried out, subjects move on
to the “postemergency-repair” health state, if the treatment
is successful, or to the “death” state.
Patients eligible for elective treatment but who refuse
to undergo repair, or who are judged unsuitable for surgery
because of the high risk of intraoperative death, especially in
comparison with their life expectancy, are collocated in the
“rejected large AAA” state.
Transition probabilities. Transition probabilities
were derived from randomized controlled trial (RCT) in-
Fig 2. The screening pathway.cluded in a recent Cochrane systematic review10 and from bhe Health Technology Assessment11 report on AAA en-
ovascular repair conducted by the UK National Institute
or Health Research. Country specific data were derived
rom local sources (Hospital Admission Database, Italian
ascular Surgery Database). Prevalence and demographic
ata were obtained from the screening program currently
ngoing at San Martino Hospital in Genova.
Table I reports all the model assumptions in terms of
ransition probabilities between health states. Transition
rom “small” to “medium” and from “medium” to “large”
AA is determined according to the different growth rates
f AAA. These states have different probabilities of rupture,
hich can lead to aneurysm-related death or to “emergency
epair” with a certain probability of surviving. It is also
ossible to receive an emergency repair without rupture
ith a different probability of surviving.
Growth rates of aneurysms, which are considered key
arameters in establishing transition probabilities between
ifferent health states, were estimated by Vardulaki et al12
nd are assumed to change exponentially over time.
Mortality for elective and emergency surgery, in both
he screening and current pathway cohorts, is different, as
emonstrated by all the RCT considered in the analy-
is.13-16 By contrast, the probabilities of transition from all
hese states to “death” for all causes are considered equal
, Abdominal aortic aneurysm.etween the groups and estimated according to age-specific
S
f
z
c
i
i
T
G
S
S
S
S
R
M
H
D
F
R
S
H
D
C
A
A
A
3
4

A
T
V
I
S
F
U
C
C
F
F
F
A
p
S
JOURNAL OF VASCULAR SURGERY
Volume 54, Number 4 Giardina et al 941life expectancy (National Institute of Statistics mortality
database 2007).
Size dependent probabilities of rupture were derived
from analyses reported by Chambers et al11 who reported
rupture rates for 3 to 3.9 cm and 4 to 4.9 cm interval and
from Powel et al meta-analysis.17 The probability of inci-
dental detection in the current pathway group was derived
from the ratio of elective surgery for AAA performed in
Italy18 and size of population with AAA 5 cm according
to the prevalence estimated by S.A.Ge program. The rup-
ture rate in “rejected” patients was obtained from another
study published in 2002 by Lederle et al.19
Transitions between health states were simulated by
using 6-month cycles; thus, every 6 months, a subject can
move to another health state with a certain transition
probability. Annual probabilities have been converted to fit
cycle length by exponential rate-to-prob function.
Quality of life was estimated by data collected during
S.A.Ge screening program. Time-dependent utility decre-
ment was estimated by a linear regression model (U 
  age  K) starting from an utility value of 0.86.
Table II shows the preliminary findings and cohort
characteristics of the screening program conducted at San
Martino Hospital while a more detailed description of the
screening program has been presented by Palombo et al.21
Resource use and costs. Costs of inviting subjects for
screening and treatment for AAA were calculated by using
a bottom-up approach from the screening program carried
out by San Martino Hospital in Genova. These costs in-
clude cost of invitation (printing and sending invitations),
advertisements, and call center employees. The costs of
screening examinations (visit and US) were estimated on
Table I. Transition probabilities (per year)
Variable Value Source
From small AAA to medium AAA 7% 12
From small to large AAA 3.8% 12
From medium to large AAA 14% 12
Incidental detection 20% 18
Rupture mortality pre-hospital 60.2% S.A.Ge
Rupture rate AAA 4 cm 0.27% 11
Rupture rate AAA 4 cm-4.9 cm 1.2% 11
Rupture rate AAA 5 cm 18.3% 17
Rupture rate in “rejected” patients 11.5% 19
Rupture in patients scheduled for
surgery 1.48% 13
Patients unfits or refusing surgery 27% S.A.Ge
Emergency surgery mortality
(ruptured) 37% 20
Emergency surgery mortality
(without rupture) 20% 20
Elective surgery mortality
(30 days)
0.7% 20
All-cause mortality rate Age-specific ISTAT 2007
Quality of life: health state
preference (utility) 0, 86 S.A.Ge
AAA, Abdominal aortic aneurysm; ISTAT, National Institute of Statistics;
S.A.Ge, Screening Abdominal Aortic Aneurysm Genova project.the basis of resource consumption observed during the w.A.Ge program, and corresponding follow-up was derived
rom the “Nomenclatore Tariffario Regionale delle presta-
ioni Ambulatoriali”.22 Table III details all cost items
onsidered in the model and their related sources.
Sensitivity analysis. Uncertainty regarding the input
nto the model was tested by means of univariate, multivar-
ate, and probabilistic sensitivity analyses (PSA). PSA is
able II. Screening Abdominal Aortic Aneurysm
enova (S.A.Ge) project screening: preliminary results
ubject Value
ubjects invited 7024
ubject attending the
screening
4327
ite used for screening Outpatient clinic of the Vascular and
Endovascular Surgery Unit at the
San Martino University Hospital in
Genoa
isk factors Subjects with AAA Subjects without
AAA
ean age (years) 74.8  5.7 72.3  7.9
eart disease 30% 25%
iabetes 12% 7%
amily predisposition
for cardiovascular
disease
59% 22%
espiratory disease 39% 38%
moking 68% 66%
ypertension 70% 74%
yslipidemia 32% 31%
hronic renal
insufficiency
18% 20%
neurysmal disease 226 (13.5%)
bdominal aortic and
aortoiliac aneurysm
127 (4.8%)
bdominal aortic 127
.0-3.9 cm diameter 64 (50.4%)
.0-4.9 cm diameter 45 (35.4%)
5 cm diameter 18 (14.2%)
AA, Abdominal aortic aneurysm.
able III. Costs and resource consumption
ariable Value Source
nvitation for screening per patient
(including printing, mailing,
advertising, call center) €2.6/$3.6 S.A.Ge
creening examination €61/$84 S.A.Ge
irst visit €11/$15 S.A.Ge
S test €50/$69 S.A.Ge
ost of emergency AAA treatment
(including EVAR and OS) €15,602/$21,646 S.A.Ge
ost of AAA elective treatment
(including EVAR or OS) €11,883/$16,486 S.A.Ge
ollow-up visit €12.9/$17.8 21
ollow-up after treatment (A-CT) €175/$242 21
ollow-up after treatment (US) €50/$69 21
AA, Abdominal aortic aneurysm; A-CT, abdominal computer tomogra-
hy; EVAR, endovascular aneurysm repair; OS, open surgery; S.A.Ge,
creening Abdominal Aortic Aneurysm Genova project; US, ultrasound.idely used to evaluate the uncertainty of model results by
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October 2011942 Giardina et alvarying the input parameters simultaneously. It enables the
accuracy of the model to be evaluated by converting uncer-
tainties surrounding the input variables into a probability
distribution.
In accordance with the most recent methodological
guidelines, the method-of-moments technique was utilized
to obtain the beta distribution of the probabilities, while a
gamma function was used for costs, assuming a standard
deviation of 10% of the value used in the base case analysis.
RESULTS
Cost-effectiveness evaluation. Total costs per invited
subject were €290 (US $402, exchange rate 1 euro 
1.3874 United States dollars) and €350 (US $485) for the
“no screening” and “screening” cohorts, respectively.
Considering an attendance rate of 62%, the individual
incremental cost per invited subject was €60 (US $83),
while additional QALY amounted to 0.011 per patient in
the screened cohort, corresponding to an ICER of €5673/
QALY (US $7870/QALY). Table IV shows the corre-
sponding results without applying the 3% discount rate to
both costs and health benefits. In this case, when no
screening for AAA is performed, the total costs were €357
(US $495), while the cost of screening was calculated to be
€417 (US $578).
Without discounting, the additional individual cost per
invited subject was estimated as €60 (US $83), while addi-
tional QALYs gained amounted to 0.014 per patient in the
screening scenario, corresponding to an ICER of €4238/
QALY (US $5879/QALY).
Clinical benefits. Incidence of ruptured aneurysm was
0.026%/y in the screened cohort, while in the nonscreened
cohort it was 0.050%/y (relative risk reduction 0.48). Inci-
dence of elective repair implementing a screening program
was 0.068%/y, while in the nonscreened cohort it was
Table IV. Incremental cost-effectiveness ratio
Screening
No
screening Difference
Total costs per invited
subject €350/$485 €290/$402 €60/$83
Total life years 13.115 13.101 0.014
Total QALY 10.354 10.343 0.011
ICER €4415/$6125/LYS
€5673/$7870/QALY
Total costs per invited
subject (not
discounted) €417/$578 €357/$495 €60/$83
Total life years (not
discounted) 17.023 17.005 0.018
Total QALY (not
discounted) 13.314 13.300 0.014
ICER €3270/$4536/LYS
€4238/$5879/QALY
ICER, Incremental cost-effectiveness ratio; LYS, life years saved; QALY,
quality adjusted life years.0.036%/y. iThe number of subjects who need to be screened to
void an AAA rupture is 540, while the number needed to
e screened to prevent an AAA-related death is 190.
Sensitivity analysis. The results of one-way sensitivity
nalysis are shown in Table V. The input parameters used to
est the strength of themodel were derived from a literature
eview. Sensitivity analysis showed that the results of the
odel were sensitive to some parameter variations but
onsistent with the base case scenario. For example, in-
reasing the attendance rate changed the results in terms of
CER, life years saved and cost per patient, ranging from
11 (US $15) per patient with a related QALY of 0.002 for
n attendance rate of 10% to €94 (US $130) with an QALY
alue of 0.022 for an attendance of 99%.
The parameter “incidental detection” also led to a
ecrease in the ICER from €3493 (US $4846) to an
ncrease up to €8541 (US $11,585) for rates of 5% and
5%, respectively.
A multivariate sensitivity analysis has been conducted
n age-specific AAA prevalence, based on subgroup analy-
is from the serial analysis of gene expression screening
rogram. Results reported in Table VI show that ICER
ncreases for older target population. Effectiveness of the
creening program is related both to prevalence (which
ncreases in older population) and to life expectancy so the
ase case scenario shows the lower ICER.
The results of the probabilistic sensitivity analysis in
erms of mean and standard deviation yielded an ICER of
5445/QALY (US $7554) (€862). These are shown on
he cost-effectiveness plane and acceptability curve in Figs 3
nd 4. Cost-effectiveness plane represents the results ob-
ained by randomly varying model parameter multiple
imes. All the points under the line represent cases that are
ost-effective for the given cost-effectiveness threshold.
he higher the proportion of point under the threshold,
he more consistent the result obtained.
The cost-effectiveness acceptability curve represents
he probability that introducing a screening programwould
e cost-effective for any given threshold. The model is
onsistent with variation of parameters: indeed, assum-
ng a willingness-to-pay threshold23 of €50,000/QALY,
creening for AAA is seen to be cost-effective, with a
robability approaching 100%.
ISCUSSION
The results obtained from our model show that imple-
enting a screening program can significantly reduce mor-
ality rates associated with AAA, avoid AAA ruptures thanks
o early diagnosis, and increase the life expectancy of those
ho undergo screening. These benefits are enhanced by
he cost evaluation: the Markov model shows that a screen-
ng program for AAA could be considered cost-effective in
he Italian NHS perspective, given a €50,000/QALY22
hreshold. These results are consistent with the economic
valuations of AAA screening programs developed in other
ountries, such as the UK, Canada, and The Netherlands.
In their analysis, Boll and colleagues24 established that
mplementing an AAA screening program increases life
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cost of €300 leading to an ICER of €1176/LYS. Results
from a similar analysis for Canada25 published in 2008
reported that a screening program produced a gain in life
expectancy of 0.049 years and a gain in discounted QALY
of 0.019, with a cost-utility ratio of CAN$6194 per QALY
gained.
Although such studies may differ in design, definitions
of health states, and parameters evaluated, all have con-
cluded that screening programs for specific cohorts of
patients are “good value for money.”
Different results have been obtained by Ehlers et al26
who evaluated cost-effectiveness of screening for Danish
men aged 65. According to their analysis screening for AAA
does not seem to be cost-effective with an ICER of
Table V. Sensitivity analysis
Parameter Rate
Base case analysis — €44
Attendance rate 10% €54
99% €43
Incidental detection 5% €26
35% €51
Rupture rate in patients scheduled
for surgery 0% €43
16% €48
Rupture rate large AAA 10% €94
22% €49
Discount rate 0% €32
5% €53
Mortality elective surgery 5% €46
AAA, Abdominal aortic aneurysm; ICER, incremental cost-effectiveness ra
Table VI. Sensitivity analysis for different age and prevale
Age (years)
Prevalence
3.0-3.9 cm
Prevalence
4.0-4.9 cm
Prevalence
5 cm
71–75 2.75% 1.50% 0.50%
76–80 2.56% 2.56% 1.36%
81–85 2.29% 2.94% 0.98%
86 6.25% 2.68% 0.89%
ICER, Incremental cost-effectiveness ratio.
Fig 3. Scatterplot of the incremental cost-effectiveness ratio.£43,485/QALY. These results have been widely dis- oussed,27 and more than one reason has been pointed out
o explain different conclusions about cost-effectiveness of
creening. Some of these differences can be found also
omparing our model to Ehlers’s work: Ehlers and col-
eagues have modeled the effects of screening 65-year-old
en, whereas our model is based on a cohort screened at
ge 65 to 75. Another important difference is the higher
isk of rupture of large AAA that in our model has been
stimated for AAA 5 cm instead of for AAA in the range
R Increase life years Cost per patient
6125 0.014 €60/$83
7522 0.002 €11.8/$16.3
6150 0.022 €93/$129
3701 0.045 €119.83/$166.2
7168 0.011 €55.27/$76.6
6078 0.014 €59.9/$83
6782 0.012 €58.59/$81.28
13,165 0.006 €55.75/$77.3
6907 0.012 €61.32/$85
5879 0.018 €60/$83.2
7368 0.011 €59/$81.8
6387 0.013 €60/$83
ICER
Increase life
year Cost per patient
3437.24/$4768 0.043 €146.86/$203.7
3754.61/$5209 0.052 €196.17/$272
5901.06/$8187 0.031 €183.86/$255
10,227.93/$14,190 0.020 €209.58/$290.7
Fig 4. Acceptability curve.ICE
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assumed by Ehlers and colleagues.
To allow an easier comparison among the cited studies,
incidence, mortality, and rupture rates have been summa-
rized in Table VII. These results can be considered relevant
although they are derived from a Markov model that is a
simulation and a simplification of the real world. This
implies that the results are likely to be less precise than those
from a randomized controlled trial; on the other hand, a
trial on the benefits of AAA screening would only yield final
results after at least 20 years.
The best evidence from an RCT that evaluated cost-
effectiveness of screening for AAA is the 10-year results of
the Multicentre Aneurysm Screening Study (MASS).13 Re-
sults show an ICER of £7600/LYG, 155 AAA related
deaths in the invited group compared with 296 in the
control group (relative risk reduction of 48%), 552 elective
operation in the invited group, and 226 in the control
group. Our model predicts the 10-year results from MASS
trial and can be validated against the finding of this trial:
ICER €7461/LYG, 158 AAA related deaths in the invited
group compared with 307 in the control group (relative
risk reduction of 48.5%), 558 elective surgery in the
Table VII. Comparison with previous study
Study
Prevalence
AAA 2.9 cm
Rate of ruptur
according to
AAA size
Boll et al24 2% (AAA 2.9 cm) NA
Montreuil et al25 3.12% (3-4.4 cm)
0.53% (4.4-5.4 cm)
0.44% (5.5 cm)
0.2% (3-4.4 cm)
2% (4.4-5.4 cm
16% (5.5 cm)
Ehlers et al26 4% (AAA 2.9 cm) 0.3% (3-4.4 cm)
1.5% (4.4-5.4 cm
6.5% (5.5 cm)
AAA, Abdominal aortic aneurysm; ICER, incremental cost-effectiveness ra
Table VIII. Analysis of potential bias
Assumption
No specific health states for urgency cases
(“emergency” repair without rupture)
This case is a
states, incr
No effect of cardiovascular prevention for
detected AAA
Reduced pot
screening
No difference between elective surgery
mortality in the screened and not
screened cohort
Reduced pot
screening
Quality of life Quality of lif
after AAA
Static assumption for rupture risk in AAA
5
Greater aneu
probability
No decrease in long-term life expectancy
after AAA repair
Reduced life
complicati
US sensitivity 100% Does not acc
One time screening program Aneurysm di
risk of rup
AAA, Abdominal aortic aneurysm; US, ultrasound.screened group, and 227 in the control group. rDespite the predicted capacity, our analysis has some
imitations that could be bias for or against the screening
hat has been summarized in Table VIII. The first is
elated to one of the key assumptions of the model, ie,
he evaluation of a prevalence (one-time) screening pro-
ram. This kind of analysis is generally simpler than the
valuation of incidence (repeat) screening, as it is related
o a specific age; however, it can underestimate or over-
stimate the effect of a screening program. The assump-
ion according to which, if no AAA is found during
creening, patients will not undergo a second US test is
ustified by the literature, which reports that the risk of
upture increases as a function of AAA size. For this
eason, all persons in whom screening is negative, which
n our model means an aortic aneurysm diameter3 cm,
re assumed not to be at risk of rupture (this is a bias for
creening) and, hence, will die of other causes by the end
f the simulation time.
On the other hand, the static assumption of rupture risk
s a bias against screening because greater aneurysms, espe-
ially above 5 to 6 cm, grow faster and have an increased
isk of rupture. As in our model, since estimates from a
Operative mortality ICER
6.8% (elective repair); 50% (emergency) €1176/LYG
4.5% (elective repair); 41% (emergency) Can$6194/QALY
3.8% (elective repair); 45% (emergency) £43,485/QALY
S, life years saved; QALY, quality adjusted life years; US, ultrasound.
Potential bias Bias direction
nted for in the elective repair health
g elective repair mortality
Against screening
l benefit on life years gained for
t
Against screening
l benefit on life years gained for
t
Against screening
be age dependent and reduced
r
Favor screening
grows faster and rupture
eases
Against screening
ctancy after AAA repair due to
omorbidities are not accounted for
Favor screening
for false negative Favor screening
r 3 cm is assumed not to be at Favor screeninge
)
)ccou
easin
entia
cohor
entia
cohor
e can
repai
rysm
incr
expe
on/c
ount
amete
tureelatively short observation period were used, the assump-
11
1
1
1
1
1
1
1
1
2
2
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tive.
There is also a potential limitation in the simplifying
hypothesis of no outcome differences between EVAR
and OS; this assumption was made to avoid complicating
the structure of the model by introducing a submodel to
evaluate the outcome of different approaches to AAA
repair.
Another limitation is that the same long-term survival
data were used concerning AAA repaired cases and nonre-
paired AAA cases except for AAA related death, and this is
a bias for screening even if it is partially offset by the
assumption that there are no benefits from early detection
and start of general cardiovascular prevention in screen-
detected cases.
Another key assumption, in agreement with other
similar studies,28,29 is that surgery would be offered to all
subjects in whom an aneurysm larger than 5 cm is
detected. Different thresholds could lead to different
results in terms of cost-effectiveness as shown in the
sensitivity analysis.
The last assumption that could be a bias for screening
and that does not differ among published studies is the
sensitivity rate of the US test, which has generally been
assumed to be 100%. Further analyses should be carried
out to define the role of screening in subgroups at high
risk or in the female population. Although a low preva-
lence of AAA has been observed in the general female
population, if risk factors are considered, the prevalence
in women could be similar to that of the general male
population, thereby justifying the screening of selected
female populations.
Despite the above-mentioned limitations, this study
demonstrated that organizing a screening program for
AAA in 65- to 75-year-oldmen is a cost-effective strategy at
a cost-effectiveness threshold of €50,000/QALY, com-
monly accepted in Italy.23
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16:22-34.ubmitted Sep 3, 2010; accepted Mar 12, 2011.INVITED COMMENTARYJes S. Lindholt, MD, PhD, and Rikke Søgaard, MS
Health economic modeling is a branch of decision-analytic
modeling often undertaken for the purpose of economic evalua-
tion of health care technologies. It has been defined by its appli-
cation of mathematical techniques to synthesize available informa-
tion about healthcare processes and their implications, thereby
providing an explicit two-way bridge between primary data and the
decisions they inform.1
The role of health economic modeling for informing policy
decisions have evolved rapidly over the past decade. In particular,
since the National Institute for Health and Clinical Excellence
(NICE) in 2004 published their updated guideline on how to
appraise new and existing technologies, it could be read to favor
modeling over trial-based studies for the purpose of economic
evaluation.2
The benefit of screening for abdominal aortic aneurysm
(AAA) has been demonstrated in large clinical trials and several
cost-effectiveness evaluations have followed from the UK, Finland,
USA, Canada, Sweden, The Netherlands, France, and Denmark.
While there is no reason to suspect that AAA behave differently
across the borders concerning growth and rupture, structural
differences in populations and health care systems typically restrict
the results to specific settings. For example, there will be variation
concerning attendance, prevalence of AAA, incidental detection
rates, proportion of ruptures reaching surgery, proportion fit for
repair, surgical outcomes, survival, and costs.
The present Italian model establishes a model structure that is
comparable to what we have seen in previous models. The popu-
lation of the model is largely based on relevant national and
international sources, although they have been selected qualita-
tively (and not upon systematic literature search and/or meta-PH, PhD, Viborg, Denmark
Concerns have been raised about the credibility of health
conomic models due to a lack of transparency of earlier reports.3
n a forthcoming review on recent models of screening for AAA,
e observed some improvements on the previously identified poor
eporting standards.4 However, a lack of model validation (com-
aring model outputs to observed outputs of eg, a randomized
linical controlled trial or to national mortality statistics) remains a
hreat to the credibility of health economic models, including the
resent Italian model. Furthermore, it is our view that modeling
omplex regimens of eg, screening for AAA usually cannot be
ppropriately documented in a scientific manuscript of three to
000 works. A separate technical paper is therefore warranted to
ake the methodology fully transparent and to justify the under-
ying assumptions. A health economic model inherently is a sim-
lified representation of the real world.
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